Responses
Clinical/translational cancer immunotherapy
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL
Compose a Response to This Article
Other responses
No responses have been published for this article.
